A case of SAPHO syndrome with diffuse sclerosing osteomyelitis of the mandible treated successfully with prednisolone and bisphosphonate

Journal of Oral and Maxillofacial Surgery

Volumn 70, Issue 3, 2012, Pages 626-631

  Hatano, Hiroko ^a   Shigeishi, Hideo ^a   Higashikawa, Koichiro ^a   Shimasue, Hiroshi ^a   Nishi, Hiromi ^a   Oiwa, Hiroshi ^b   Shindo, Hajime ^a   Takechi, Masaaki ^a   Ohge, Hiroki ^a   Kamata, Nobuyuki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CLARITHROMYCIN; FLOMOXEF; PREDNISOLONE; RISEDRONIC ACID; TECHNETIUM 99M; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID;

ADULT; ARTICLE; CASE REPORT; COMPLEMENT HEMOLYSIS TEST; COMPUTER ASSISTED TOMOGRAPHY; DECORTICATION; DIFFUSE SCLEROSING OSTEOMYELITIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; HUMAN; HYPERBARIC OXYGEN; JAW DISEASE; JAW RADIOGRAPHY; LEUKOCYTE COUNT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; OSTEOMYELITIS; OSTEOSCLEROSIS; SAPHO SYNDROME; DRUG COMBINATION; MANDIBLE; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; SCLEROSIS; TREATMENT OUTCOME;

ACQUIRED HYPEROSTOSIS SYNDROME; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; MALE; MANDIBLE; MANDIBULAR DISEASES; MIDDLE AGED; OSTEOMYELITIS; PREDNISOLONE; SCLEROSIS; TREATMENT OUTCOME;

EID: 84859930444     PISSN: 02782391     EISSN: 15315053     Source Type: Journal    
DOI: 10.1016/j.joms.2011.04.010     Document Type: Article

References (24)

1. Chamot AM, Benhamou CL, Kahn MF, et al: [Acne-pustulosishyperostosis- osteitis syndrome. Results of a national survey. 85 Cases]. Rev Rhum Mal Osteoartic 54:187, 1987
2. Benhamou CL, Chamot AM, Kahn MF: Synovitis-Acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 6:109, 1988
3. Kahn MF, Hayem F, Hayem G, et al: Is diffuse sclerosing osteomyelitis of the mandible part of the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome? Analysis of seven cases. Oral Surg Oral Med Oral Pathol 78:594, 1994
4. Suei Y, Taguchi A, Tanimoto K: Diffuse sclerosing osteomyelitis of the mandible: Its characteristics and possible relationship to synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. J Oral Maxillofac Surg 54:1194, 1996
5. Suei Y, Taguchi A, Tanimoto K: Diagnosis and classification of mandibular osteomyelitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:207, 2005
6. Tsukamoto H, Horiuchi T: [Clinical aspects of the complement system]. Rinsho Byori 54:757, 2006
7. Chen M, Daha MR, Kallenberg CG: The complement system in systemic autoimmune disease. J Autoimmun 34:276, 2010
8. Braun WE: HLA molecules in autoimmune diseases. Clin Biochem 25:187, 1992
9. Graham RR, Ortmann W, Rodine P, et al: Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Gene 15:823, 2007
10. Olivieri I, Padula A, Palazzi C: Pharmacological management of SAPHO syndrome. Expert Opin Investig Drugs 15:1229, 2006
11. Ben Abdelghani K, Dran DG, Gottenberg JE, et al: Tumor necrosis factor-Alpha blockers in SAPHO syndrome. J Rheumatol 37:1699, 2010
12. Hyrich KL, Silman AJ, Watson KD, et al: Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: An update on safety. Ann Rheum Dis 63:1538, 2004
13. Flendrie M, Vissers WH, Creemers MC, et al: Dermatological conditions during TNF-Alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study. Arthritis Res Ther 7:666, 2005
14. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al: Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 86:242, 2007
15. Hayem G, Bouchaud-Chabot A, Benali K, et al: SAPHO syndrome: A long-term follow-up study of 120 cases. Semin Arthritis Rheum 29:159, 1999
16. Fleuridas G, Teysseres N, Ragot JP, et al: [Diffuse sclerosing osteomyelitis of the mandible and SAPHO syndrome]. Rev Stomatol Chir Maxillofac 103:96, 2002
17. Kahn MF, Khan MA: The SAPHO syndrome. Baillieres Clin Rheumatol 8:333, 1994
18. Kopterides P, Pikazis D, Koufos C: Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum 50: 2970, 2004
19. Amital H, Applbaum YH, Aamar S, et al: SAPHO syndrome treated with pamidronate: An open-label study of 10 patients. Rheumatol Oxf 43:658, 2004
20. Colina M, La Corte R, Trotta F: Sustained remission of SAPHO syndrome with pamidronate: A follow-up of fourteen cases and a review of the literature. Clin Exp Rheumatol 27:112, 2009
21. Fioravanti A, Cantarini L, Burroni L, et al: Efficacy of alendronate in the treatment of the SAPHO syndrome. J Clin Rheumatol 14:183, 2008
22. Kopterides P, Pikazis D, Koufos C: Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum 50: 2970, 2004
23. Soyfoo MS, Gangji V, Margaux J: Successful treatment of SAPHO syndrome with ibandronate. J Clin Rheumatol 16: 253, 2010
24. Wright SA, Millar AM, Coward SM, et al: Chronic diffuse sclerosing osteomyelitis treated with risedronate. J Rheumatol 32: 1376, 2005